You are here

Our science / Clinical Trials / Find a Trial / NCT01243151

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Back to Search Print Save as PDF Bookmark Trial

NCT01243151

Last updated on December 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Culver City, California, 90232 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypercholesterolemia, Dyslipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- LDL-C must be greater or equal to 130 mg/dl

- BMI must be between 18.5 and 40 kg/m2

- Japanese volunteers must have 4 Japanese grand parents born in Japan

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of cardiovascular or cerebrovascular event during the past year.

- Poorly controlled type 1 or type 2 diabetes mellitus

- Subjects who have taken lipid lowering therapies within the last 3 months of
screening.

NCT01243151
Pfizer
Completed
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Primary Hyperlipidemia or Mixed Dyslipidemia
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
NCT02947334
All Genders
18+
Years
Beijing, Beijing
Hypercholesterolemia
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects
NCT01720537
All Genders
18+
Years
Multiple Sites
Healthy, Hypercholesterolemia
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase
NCT02667223
All Genders
18+
Years
Brussels,
Dyslipidemia
Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
NCT00673660
All Genders
18+
Years
Multiple Sites
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of PF-04950615 (RN316) In Healthy Adult Subjects With Hypercholesterolemia
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Hypercholesterolemia
  • Dyslipidemia
Biological: PF-04950615 (RN316)
Infusion every week
  • Placebo Comparator: A
    Intervention: Biological: PF-04950615 (RN316)
  • Experimental: B
    Intervention: Biological: PF-04950615 (RN316)
  • Experimental: C
    Intervention: Biological: PF-04950615 (RN316)
  • Experimental: D
    Intervention: Biological: PF-04950615 (RN316)
  • Experimental: E
    Intervention: Biological: PF-04950615 (RN316)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • LDL-C must be greater or equal to 130 mg/dl
  • BMI must be between 18.5 and 40 kg/m2
  • Japanese volunteers must have 4 Japanese grand parents born in Japan

Exclusion Criteria:

  • History of cardiovascular or cerebrovascular event during the past year.
  • Poorly controlled type 1 or type 2 diabetes mellitus
  • Subjects who have taken lipid lowering therapies within the last 3 months of screening.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01243151
B1481009
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now